Werewolf Therapeutics, Inc. (NASDAQ:HOWL – Get Free Report) has earned a consensus rating of “Hold” from the seven research firms that are covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, four have issued a hold recommendation and two have assigned a buy recommendation to the company. The average 12-month price target among brokerages that have covered the stock in the last year is $3.75.
HOWL has been the subject of several research reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Werewolf Therapeutics in a research note on Monday, April 20th. Wall Street Zen downgraded Werewolf Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th.
Get Our Latest Research Report on HOWL
Werewolf Therapeutics Stock Performance
Werewolf Therapeutics (NASDAQ:HOWL – Get Free Report) last released its quarterly earnings results on Thursday, May 7th. The company reported ($0.28) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.32) by $0.04. Sell-side analysts predict that Werewolf Therapeutics will post -1.29 EPS for the current year.
Insider Buying and Selling at Werewolf Therapeutics
In other news, Director Luke Evnin sold 305,741 shares of Werewolf Therapeutics stock in a transaction on Friday, May 8th. The stock was sold at an average price of $0.70, for a total transaction of $214,018.70. Following the completion of the transaction, the director owned 1,273,008 shares of the company’s stock, valued at $891,105.60. The trade was a 19.37% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, major shareholder Ra Capital Management, L.P. sold 376,526 shares of Werewolf Therapeutics stock in a transaction on Friday, May 8th. The stock was sold at an average price of $0.71, for a total value of $267,333.46. Following the transaction, the insider directly owned 418,813 shares of the company’s stock, valued at $297,357.23. This trade represents a 47.34% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 1,916,663 shares of company stock valued at $1,250,874 in the last ninety days. Corporate insiders own 23.60% of the company’s stock.
Institutional Trading of Werewolf Therapeutics
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Regal Investment Advisors LLC increased its position in Werewolf Therapeutics by 93.3% during the 4th quarter. Regal Investment Advisors LLC now owns 52,593 shares of the company’s stock worth $33,000 after purchasing an additional 25,389 shares in the last quarter. Vontobel Holding Ltd. increased its position in Werewolf Therapeutics by 66.7% during the 4th quarter. Vontobel Holding Ltd. now owns 60,003 shares of the company’s stock worth $38,000 after purchasing an additional 24,003 shares in the last quarter. Renaissance Technologies LLC increased its position in Werewolf Therapeutics by 48.6% during the 4th quarter. Renaissance Technologies LLC now owns 677,766 shares of the company’s stock worth $429,000 after purchasing an additional 221,766 shares in the last quarter. Susquehanna International Group LLP increased its position in Werewolf Therapeutics by 16.9% during the 3rd quarter. Susquehanna International Group LLP now owns 93,041 shares of the company’s stock worth $183,000 after purchasing an additional 13,439 shares in the last quarter. Finally, Citadel Advisors LLC purchased a new stake in Werewolf Therapeutics during the 3rd quarter worth about $304,000. Hedge funds and other institutional investors own 64.84% of the company’s stock.
Werewolf Therapeutics Company Profile
Werewolf Therapeutics, Inc (NASDAQ: HOWL) is a clinical-stage biotechnology company focused on the development of next-generation immunotherapies for the treatment of solid tumors. The company’s proprietary Conditional Activation Platform is designed to keep therapeutic molecules inert in healthy tissues and selectively activate them within the tumor microenvironment, aiming to enhance anti-tumor efficacy while minimizing systemic toxicity.
Leveraging this platform, Werewolf Therapeutics is advancing multiple programs that include conditionally activated cytokine candidates and bi-specific antibody constructs.
Read More
- Five stocks we like better than Werewolf Therapeutics
- Abercrombie Rallies as Strong Q1 Earnings Extend Winning Streak
- TeraWulf Bets on Power Infrastructure to Lead AI Build-Out
- Amazon’s Alexa for Shopping Strengthens an Already Strong Bull Case
- Keysight: The AI and Defense Stock Seeing Big Price Target Boosts
Receive News & Ratings for Werewolf Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Werewolf Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
